April 15, 2021 - The first recruits were injected today to start the Phase I trial of Entos Pharmaceuticals’ made-in-Canada COVID-19 DNA vaccine, Covigenix VAX-001! The Canadian Center for Vaccinology in Halifax, Nova Scotia is conducting the trial.

Like the globally approved mRNA vaccines, Entos’ DNA vaccine delivers the information needed for our cells to make the spike protein to stimulate a protective immune response against SARS-CoV-2.However, Entos’ Covigenix DNA vaccine is more stable at fridge and room temperatures and cheaper to upscale and manufacture millions of doses.

“We need to get 16 billion doses worldwide to beat this pandemic, and we believe DNA is the perfect way to approach that,” said John Lewis, CEO Entos Pharmaceuticals.

Read more about Entos and DNA vaccines from the University of Alberta

Or listen to the podcast SHIFT by Alberta Innovates with Entos Pharmaceuticals CEO John Lewis about the journey to conquer COVID-19. Season 2 - Episode 2

Entos Pharmaceuticals

33 St James's Square
London, UK, SW1Y 4JS

Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

3040 Science Park Road, Suite 1100
San Diego, CA 92121

General Contact
Tel: 1-800-727-0884
Email: info@entospharma.com

Investor Contact
Email: info@entospharma.com

Media Contact
Email: media@entospharma.com

Careers Contact
Email: careers@entospharma.com‍
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.